EP Patent

EP2004172B1 — Drug delivery structures and compositions for nasolacrimal system

Assigned to Mati Therapeutics Inc · Expires 2019-03-13 · 7y expired

What this patent protects

Patent listed against Gemzar.

Drugs covered by this patent

Gemzar (Gemcitabine Hydrochloride) · Accord Hlthcare

Patent Metadata

Patent number: EP2004172B1
Jurisdiction: EP
Classification: —
Expires: 2019-03-13
Drug substance claim: No
Drug product claim: No
Assignee: Mati Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.